URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$46.86
0.06 (0.13%)
▲
5d:
-2.82%
30d:
+10.26%
90d:
+56.83%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$90.05
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$55.92
16.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $46.86, which is considered extended relative to its 30-day fair value range of $39.63 to $47.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.8) compared to its historical average (23.0). Remarkably, the market is currently pricing in an annual earnings decline of 10.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $45.34, while resistance sits at $50.81.
Market Sentiment: URGN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+28.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $45.34, while resistance sits at $50.81.
Market Sentiment: URGN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+28.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$39.63 -
$47.22
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.0% below Wall St target ($60.00)
Trading Range Analysis
30-Day Trading Range
$39.63 -
$47.22
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$45.34
Resistance Level
$50.81
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.77
Wall Street Target
$60.00
(+28.0%)
Revenue Growth (YoY)
199.2%
Profit Margin
-51.7%
Valuation Discount vs History
-10.0% cheaper
PE vs Historical
16.8 vs 23.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.0%
(market-implied from PE analysis)
1-Year Target
$42.17
(-10%)
2-Year Target
$37.96
(-19%)
3-Year Target
$34.16
(-27%)
3-Yr Target (if PE normalizes)
(PE: 17→23)
$46.85
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.8 to 23.0
Stabilization Target:
$64.27
(+37.2%)
PE Expansion Potential:
+37.2%
Share & Embed Analysis
Last updated: August 24, 2026 2:14 AM ET
Data refreshes hourly during market hours. Next update: 3:14 AM
Data refreshes hourly during market hours. Next update: 3:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
